Physician profile

E P Roy

Neurology (Psychiatry & Neurology) · State College, PA

NPI 1164485397

$6,122.90

in general payments reported to CMS, 2019-2025

46 companies · $466 in 2025

The $466 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,978.85

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Teva Pharmaceuticals USA, INC. $1,657.70 2019-2025 Austedo Xr, Austedo, Austedo Xr
Abbvie INC. $1,173.35 2019-2025 Ubrelvy, Botox, Duopa
Acadia Pharmaceuticals INC $309.88 2019-2023 Nuplazid
Novartis Pharmaceuticals Corporation $287.48 2019-2023
Emd Serono, INC. $225.32 2019-2025 Mavenclad
Lundbeck LLC $205.40 2019-2025 Vyepti, Rexulti
Lilly USA, LLC $178.28 2019-2024 Emgality, Reyvow, Amyvid
Mdd US Operations, LLC $144.71 2019-2024 Gocovri, Gocovri
Biogen, INC. $139.89 2019-2023 Tysabri
Ucb, INC. $135.66 2019-2022
Celgene Corporation $133.43 2021-2023 Zeposia
Amneal Pharmaceuticals LLC $124.62 2019-2024 Rytary
Supernus Pharmaceuticals, INC. $116.75 2019-2021
Alexion Pharmaceuticals, INC. $92.70 2019-2023 Ultomiris
Amgen INC. $80.86 2019-2023 Aimovig
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Genzyme Corporation $79.29 2019-2021
Jazz Pharmaceuticals INC. $73.28 2019-2023
Neurocrine Biosciences, INC. $67.64 2019-2025 Ongentys, Ingrezza
Kyowa Kirin, INC. $67.57 2019-2023 Nourianz
Genentech USA, INC. $66.11 2019-2025 Ocrevus Zunovo, Ocrevus
Impel Pharmaceuticals INC. $64.48 2023 Trudhesa
Harmony Biosciences LLC $58.57 2021-2022
Upsher-Smith Laboratories LLC $52.30 2019-2022
Eisai INC. $50.99 2022
Livanova USA, INC. $50.92 2023 Vns Therapy Sentiva Model 1000 Generator
Allergan, INC. $44.94 2020-2021
Pfizer INC. $44.28 2023
Janssen Pharmaceuticals, INC $42.11 2022
Sk Life Science, INC. $30.75 2021-2023
Ge Healthcare $28.84 2022-2023
Catalyst Pharmaceuticals, INC. $27.47 2021
Csl Behring $26.88 2019
Xeris Pharmaceuticals, INC. $22.49 2023 Keveyis
Si-Bone, INC. $19.85 2019
E.R. Squibb & Sons, L.L.C. $19.47 2020
Argenx US, INC. $19.45 2023 Vyvgart
Metacel Pharmaceuticals LLC $19.32 2023 Ozobax
Bausch Health US, LLC $18.89 2019
Collegium Pharmaceutical, INC. $18.59 2022
Astrazeneca Pharmaceuticals Lp $17.66 2022
Tg Therapeutics, INC. $15.68 2023
Avanir Pharmaceuticals, INC. $14.75 2019
Sunovion Pharmaceuticals INC. $14.37 2021
Promius Pharma LLC $13.50 2019
Nevro Corp. $13.39 2022
Biohaven Pharmaceuticals, INC. $13.04 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

E P Roy

$6,122.90

in general payments reported 2019-2025

Years
2019-2025
Top company
Teva Pharmaceuticals USA, INC.
Context
The $466 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).

https://glasscript.com/doctor/7216/e-p-roy

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.